Aquestive Therapeutics, Inc. (AQST)
NASDAQ:AQST
Want to see AQST full AI Analyst Report?
AQST Stock Chart & Stats
$4.32
-$0.11(-3.57%)
At close: 4:00 PM EST
$4.32
-$0.11(-3.57%)
Day’s Range― - ―
52-Week Range$2.68 - $7.55
Previous CloseN/A
Volume606.88K
Average Volume (3M)1.59M
Market Cap
$504.31M
Enterprise Value$422.06M
Total Cash (Recent Filing)$110.73M
Total Debt (Recent Filing)$133.58M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 04, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding125,450,120
10 Day Avg. Volume2,082,024
30 Day Avg. Volume1,587,518
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)-23.41
Price to Sales (P/S)17.69
P/FCF Ratio-14.87
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue8.40
Enterprise Value/Gross Profit13.23
Enterprise Value/Ebitda-7.62
Forecast
1Y Price Target
$8.75Price Target Upside102.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$50.52M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress — AnaphylmClear FDA engagement and alignment on study designs materially reduce regulatory execution risk. Having submitted the human factors protocol and secured Type A feedback supports a structured resubmission timeline (Type 2, ~6 months) and enables parallel international filings, improving the probability of eventual approval and predictable commercialization planning.
Improved Liquidity & Financing FlexibilityThe secured Oaktree facility combined with RTW funding and Q1 cash provides a multi-year runway into launch, lowering immediate refinancing pressure and enabling sustained commercial build (sales force, hub services). This structural funding support reduces short-term liquidity risk and allows execution on regulatory and launch milestones rather than emergency financing.
Revenue Growth And Operating DisciplineSharp year-over-year revenue improvement and meaningful reductions in SG&A and R&D demonstrate the company can scale commercial activity while managing expense base. Improved operating leverage and recurring manufacturing/royalty streams create a firmer revenue foundation that supports longer-term commercialization investments and reduces structural burn when sustained.
Bears Say
Persistent Cash Burn & Negative EquityMaterial ongoing operating and free cash-flow deficits alongside negative shareholders' equity signal structural balance-sheet weakness. Continued cash burn increases reliance on external financing, heightening dilution and covenant exposure risk if milestones slip, and limits the company’s ability to absorb cost overruns or extended regulatory timelines without additional capital.
FDA CRL Requires Additional StudiesRegulatory-mandated human factors and PK studies introduce durable timing and execution uncertainty. These studies add cost and create dependency on FDA feedback for protocol acceptance and review classification; if timelines extend or additional data are required, approval and revenue realization could be delayed materially, stressing planning and cash runway assumptions.
Launch Access Risk And Revenue LumpinessEven with approval, durable commercial hurdles exist: payer coverage, prior-authorization friction, and office-level logistics can slow uptake and pressure revenue ramp. Additionally, recent license/royalty boosts included one-time items, highlighting potential lumpiness in near-term revenue that undermines predictability and increases dependence on successful market-access execution.
Aquestive Therapeutics News
AQST FAQ
What was Aquestive Therapeutics, Inc.’s price range in the past 12 months?
Aquestive Therapeutics, Inc. lowest stock price was $2.67 and its highest was $7.55 in the past 12 months.
What is Aquestive Therapeutics, Inc.’s market cap?
Aquestive Therapeutics, Inc.’s market cap is $504.31M.
When is Aquestive Therapeutics, Inc.’s upcoming earnings report date?
Aquestive Therapeutics, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 65 days.
How were Aquestive Therapeutics, Inc.’s earnings last quarter?
Aquestive Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.064.
Is Aquestive Therapeutics, Inc. overvalued?
According to Wall Street analysts Aquestive Therapeutics, Inc.’s price is currently Undervalued.
Does Aquestive Therapeutics, Inc. pay dividends?
Aquestive Therapeutics, Inc. does not currently pay dividends.
What is Aquestive Therapeutics, Inc.’s EPS estimate?
Aquestive Therapeutics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Aquestive Therapeutics, Inc. have?
Aquestive Therapeutics, Inc. has 125,450,120 shares outstanding.
What happened to Aquestive Therapeutics, Inc.’s price movement after its last earnings report?
Aquestive Therapeutics, Inc. reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went up 14.528%.
Which hedge fund is a major shareholder of Aquestive Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AQST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aquestive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (102.55% Upside)
$8.75 (102.55% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 775.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $35.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.08%
12-Months-Change
Fundamentals
Return on Equity
190.87%
Trailing 12-Months
Asset Growth
38.04%
Trailing 12-Months
Company Description
Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQST Company Deck
AQST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call contained multiple strong positives: substantive regulatory progress, a completed Phase I safety study with promising directional biomarkers for AQST-108, materially improved Q1 financials (revenues +66%, sharply reduced net loss and non-GAAP EBITDA loss), a strengthened liquidity position via a $150M Oaktree facility and RTW extension, and active commercial and medical affairs preparations (75-person sales force plan, conference/publication program). The primary negatives are the existing FDA CRL requirements (human factors and PK studies) that make resubmission timing dependent on FDA responses, expected challenges around payer coverage and physician-office friction at launch, the one-time nature of a portion of Q1 royalty revenue, and conditional access to some debt tranches. Overall, the positives (regulatory path clarity in progress, improved financials, strong liquidity, promising pipeline signal, and concrete launch planning) outweigh the risks and remaining obstacles, though execution on studies, FDA timelines, and market access remain critical.View all AQST earnings summariesAQST Stock 12 Month Forecast
Average Price Target
$8.75
▲(102.55% Upside)
Technical Analysis
Emergent Biosolutions
―
SIGA Technologies
―
Esperion
―
Organogenesis Holdings
―
Evolus
―
Ownership Overview
2.32% Insiders
9.11% Mutual Funds
23.04% Other Institutional Investors
57.32% Public Companies and
Individual Investors